A Double-blind Study of the Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog 174; in Subjects With Type 1 Diabetes Including Assessments of Safety and Injection Site Toleration.

Trial Profile

A Double-blind Study of the Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog 174; in Subjects With Type 1 Diabetes Including Assessments of Safety and Injection Site Toleration.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2013

At a glance

  • Drugs Insulin (Primary) ; Insulin lispro
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 12 Jun 2012 Results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
    • 04 Aug 2011 Status changed from recruiting to completed, as reported in a Biodel media release.
    • 16 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top